Aarkstore - Metastatic Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
Metastatic Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Prostate Cancer. Browse full report @ http://bit.ly/1wdcwzs
Metastatic Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Prostate Cancer.
Browse full report @ http://bit.ly/1wdcwzs
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Aarkstore</strong> Enterprise<br />
<strong>Aarkstore</strong> - <strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong>-<strong>Global</strong> <strong>API</strong><br />
<strong>Manufacturers</strong>, <strong>Marketed</strong> <strong>and</strong> <strong>Phase</strong> <strong>III</strong> <strong>Drugs</strong><br />
L<strong>and</strong>scape, <strong>2015</strong><br />
Browse Full Report @<br />
http://www.aarkstore.com/pharmaceuticals-healthcare/97797/metastatic-prostate-cancer-global-apimanufacturers-marketed-<strong>and</strong>-phase-iii-drugs-l<strong>and</strong>scape-<strong>2015</strong><br />
Published: Feb <strong>2015</strong>| No. Of Pages: 100 Pages<br />
PDF: $ 2000| Site License : $ 4000 | Enterprise Wide License : $ 6000|<br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong>-<strong>Global</strong> <strong>API</strong> <strong>Manufacturers</strong>, <strong>Marketed</strong> <strong>and</strong> <strong>Phase</strong> <strong>III</strong> <strong>Drugs</strong> L<strong>and</strong>scape, <strong>2015</strong>, Report<br />
provides comprehensive insights about phase <strong>III</strong> pipeline drugs <strong>and</strong> marketed drugs across the <strong>Metastatic</strong><br />
<strong>Prostate</strong> <strong>Cancer</strong>. A key objective of DelveInsights report is to establish the underst<strong>and</strong>ing for <strong>API</strong><br />
<strong>Manufacturers</strong> for marketed <strong>and</strong> <strong>Phase</strong> <strong>III</strong> Pipeline drugs across the different countries <strong>and</strong> regions for the<br />
drugs falling under <strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong>. The Report gives insights into patents providing the patent<br />
protection data <strong>and</strong> marketing exclusivity of all the drugs across the <strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong>. While the<br />
leading br<strong>and</strong>s, companies <strong>and</strong> chemicals are considered thoroughly, DelveInsights report also provides details<br />
on the <strong>Global</strong> <strong>API</strong> <strong>Manufacturers</strong> across the globe covering Drug Master Filings of US, Europe <strong>and</strong> <strong>API</strong><br />
<strong>Manufacturers</strong> in Asia specifically China <strong>and</strong> India. The research analysis also presents the global sales<br />
forecasts data till 2016.<br />
Data Sources<br />
The report is built using data <strong>and</strong> information sourced from proprietary databases, primary <strong>and</strong> secondary<br />
research <strong>and</strong> in-house analysis by DelveInsight team of industry experts.<br />
Secondary sources information <strong>and</strong> data has been collected from various printable <strong>and</strong> non-printable sources<br />
like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade<br />
associations, Books, Industry Portals, Industry Associations <strong>and</strong> access to available databases.
<strong>Aarkstore</strong> Enterprise<br />
Please note: This report requires certain updates. We have all the information available but require 3 business<br />
days to complete the process <strong>and</strong> ensure it is as up-to-date as possible. Certain sections in the report may be<br />
removed or altered based on the availability <strong>and</strong> relevance of data for the indicated disease.<br />
Scope<br />
A snapshot of the global Market therapeutics scenario for <strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong>.<br />
A review of the marketed products under prescription for <strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong>, regulatory<br />
information <strong>and</strong> marketing status.<br />
Coverage of global patent coverage <strong>and</strong> detailed commentaries on the US patent challenges.<br />
Graphical representation of investigational products for patent expiry <strong>and</strong> market exclusivities across<br />
the globe.<br />
Product profiles for marketed products for <strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> with complete description of<br />
mechanism of action, therapeutic class, target, route(s) of administration <strong>and</strong> chemical details.<br />
Coverage of <strong>API</strong> <strong>Manufacturers</strong> for <strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> drugs in the United States, Europe <strong>and</strong><br />
Asian Regions with location details.<br />
Coverage of Regulatory filings in the US, Europe, <strong>and</strong> Asia specifically India <strong>and</strong> China for <strong>Metastatic</strong><br />
<strong>Prostate</strong> <strong>Cancer</strong> drugs.<br />
Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with <strong>Metastatic</strong> <strong>Prostate</strong><br />
<strong>Cancer</strong> drugs.<br />
Coverage of <strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> <strong>Phase</strong> <strong>III</strong> pipeline products featuring sections on product<br />
description, mechanism of action, Chemical details <strong>and</strong> research & development progress.<br />
Coverage of the United States Drug Master File (US DMF) available for <strong>Phase</strong> <strong>III</strong> Pipeline <strong>Drugs</strong>.<br />
Key discontinued <strong>Marketed</strong> products.<br />
<strong>Global</strong> Sales Figure from 2012-2016.<br />
Reasons to buy<br />
<br />
<br />
<br />
Evaluate the marketing status <strong>and</strong> exclusivity details of <strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> key products to<br />
exploit opportunities for generic drug development opportunities.<br />
Identify <strong>and</strong> underst<strong>and</strong> important <strong>and</strong> diverse types of therapeutics under <strong>Phase</strong> <strong>III</strong> development for<br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong>.<br />
Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry<br />
details <strong>and</strong> exclusivity with respect to <strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong>.
<strong>Aarkstore</strong> Enterprise<br />
<br />
<br />
<br />
<br />
<br />
<br />
<strong>API</strong> intelligence over marketed drugs for <strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> <strong>and</strong> gaining primary intelligence<br />
over active ingredients manufacturers across the globe.<br />
<strong>API</strong> intelligence over leading <strong>Phase</strong> <strong>III</strong> Pipeline drugs.<br />
Develop <strong>and</strong> design strategies by identifying the <strong>API</strong> manufacturers for <strong>Phase</strong> <strong>III</strong> Pipeline products to<br />
enhance <strong>and</strong> exp<strong>and</strong> business potential <strong>and</strong> scope.<br />
Underst<strong>and</strong>ing the scope of the <strong>Phase</strong> <strong>III</strong> <strong>Drugs</strong> with nil regulatory filings.<br />
Underst<strong>and</strong>ing the chemical route of synthesis of approved drugs for <strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong>.<br />
Uncovering opportunities in the rapidly growing US market.<br />
Browse complete Report on:<br />
http://www.aarkstore.com/pharmaceuticals-healthcare/97797/metastatic-prostate-cancer-global-apimanufacturers-marketed-<strong>and</strong>-phase-iii-drugs-l<strong>and</strong>scape-<strong>2015</strong><br />
Table of Content<br />
Indication Overview<br />
<strong>Marketed</strong> <strong>Drugs</strong><br />
<strong>Marketed</strong> Details of <strong>Drugs</strong> by Application Type<br />
<strong>Marketed</strong> Details of <strong>Drugs</strong> (NDA) by Marketing Status<br />
<strong>Marketed</strong> Details of <strong>Drugs</strong> by Patent Expiration Timeline<br />
Active Pharmaceutical Ingredient (<strong>API</strong>) <strong>Manufacturers</strong> Assessment<br />
<strong>API</strong> <strong>Manufacturers</strong> by United States Drug Master File (US DMF) Status<br />
<strong>API</strong> <strong>Manufacturers</strong> by US DMF Status (Drug Specific)<br />
<strong>API</strong> <strong>Manufacturers</strong> in Europe by Country<br />
<strong>API</strong> <strong>Manufacturers</strong> in India by State<br />
<strong>API</strong> <strong>Manufacturers</strong> in China by Province<br />
<strong>Marketed</strong> Details of Approved <strong>Drugs</strong> by Geography<br />
Active Pharmaceutical Ingredient (<strong>API</strong>) <strong>Manufacturers</strong> Assessment for <strong>Phase</strong> <strong>III</strong> Pipeline <strong>Drugs</strong><br />
<strong>API</strong> <strong>Manufacturers</strong> by US DMF Status (Drug Specific)<br />
<strong>Drugs</strong> Market Data <strong>and</strong> Forecasted Sales Figure (2012-2016)<br />
<strong>Marketed</strong> <strong>Drugs</strong> for <strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong><br />
Drug Name
<strong>Aarkstore</strong> Enterprise<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Drug Description<br />
<strong>Global</strong> Active Pharmaceutical <strong>Manufacturers</strong> for Drug<br />
Approval Status of Drug<br />
Patent <strong>and</strong> Exclusivity Details for Drug<br />
Company Profile <strong>and</strong> Financials<br />
<strong>Phase</strong> <strong>III</strong> <strong>Drugs</strong> for <strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong><br />
United States Drug Master File (DMF)<br />
Discontinued <strong>Drugs</strong> for <strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong><br />
Appendix<br />
Methodology<br />
Contact Us<br />
Disclaimer<br />
List of Tables<br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> Therapeutic Market, US, <strong>Marketed</strong> <strong>Drugs</strong> by Application Type, <strong>2015</strong><br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> Therapeutic Market, US, <strong>Marketed</strong> <strong>Drugs</strong> by Marketing Status, <strong>2015</strong><br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> Therapeutic Market, US, (Year), <strong>2015</strong><br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> <strong>Marketed</strong> <strong>Drugs</strong>, <strong>API</strong> <strong>Manufacturers</strong> by US DMF Status, <strong>2015</strong><br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> <strong>Marketed</strong> <strong>Drugs</strong>, US DMF Status Drug Specific (Number), <strong>2015</strong><br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> <strong>Drugs</strong>, <strong>API</strong> <strong>Manufacturers</strong>, Europe by Country, <strong>2015</strong><br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> <strong>Drugs</strong>, <strong>API</strong> <strong>Manufacturers</strong>, India by State, <strong>2015</strong><br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> <strong>Drugs</strong>, <strong>API</strong> <strong>Manufacturers</strong>, China by Province, <strong>2015</strong><br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> <strong>Drugs</strong>, <strong>API</strong> <strong>Manufacturers</strong> by Geography <strong>2015</strong><br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> <strong>Phase</strong> <strong>III</strong> Pipeline <strong>Drugs</strong>, US DMF Status Drug Specific (Number), <strong>2015</strong><br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> Therapeutic Market, <strong>Global</strong> Sales 2012-2016 (in million USD)<br />
<strong>API</strong> <strong>Manufacturers</strong> for Drug, <strong>2015</strong><br />
<strong>Phase</strong> <strong>III</strong> <strong>Drugs</strong> for <strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong>, <strong>2015</strong><br />
Discontinued <strong>Drugs</strong> for <strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong>, <strong>2015</strong><br />
List of Figures<br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> Therapeutic Market, US, <strong>Marketed</strong> <strong>Drugs</strong> by Application Type (%), <strong>2015</strong>
<strong>Aarkstore</strong> Enterprise<br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> Therapeutic Market, US, <strong>Marketed</strong> <strong>Drugs</strong> by Marketing Status (%), <strong>2015</strong><br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> Therapeutic Market, US, (Year), <strong>2015</strong><br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> <strong>Marketed</strong> <strong>Drugs</strong>, <strong>API</strong> <strong>Manufacturers</strong> by US DMF Status (%), <strong>2015</strong><br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> <strong>Marketed</strong> <strong>Drugs</strong>, US DMF Status Drug Specific (Number), <strong>2015</strong><br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> <strong>Drugs</strong>, <strong>API</strong> <strong>Manufacturers</strong>, Europe by Country, <strong>2015</strong><br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> <strong>Drugs</strong>, <strong>API</strong> <strong>Manufacturers</strong>, India by State, <strong>2015</strong><br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> <strong>Drugs</strong>, <strong>API</strong> <strong>Manufacturers</strong>, China by Province, <strong>2015</strong><br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> <strong>Drugs</strong>, <strong>API</strong> <strong>Manufacturers</strong> by Geography <strong>2015</strong><br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> <strong>Phase</strong> <strong>III</strong> Pipeline <strong>Drugs</strong>, US DMF Status Drug Specific (Number), <strong>2015</strong><br />
<strong>Metastatic</strong> <strong>Prostate</strong> <strong>Cancer</strong> Therapeutic Market, <strong>Global</strong> Sales 2012-2016 (in million USD)<br />
Drug, Patent/Exclusivity Expiry (Year), <strong>2015</strong><br />
Related reports:<br />
<br />
Pharmaceutical Industry in China<br />
Healthcare IT Market in India <strong>2015</strong>-2019<br />
<br />
<br />
<br />
Annual Report Analysis of Listed Amino Acid Companies in China<br />
Vitamin Price in China<br />
Vitamin Industry Trend in China<br />
<strong>Global</strong> POC Diagnostics Market <strong>2015</strong>-2019<br />
<strong>Global</strong> POC Lipid Testing Market <strong>2015</strong>-2019<br />
<strong>Global</strong> Sexual Wellness Market <strong>2015</strong>-2019<br />
Healthcare IT Market in Africa <strong>2015</strong>-2019<br />
Healthcare IT Market in India <strong>2015</strong>-2019
<strong>Aarkstore</strong> Enterprise<br />
About <strong>Aarkstore</strong> Enterprise<br />
<strong>Aarkstore</strong> Enterprise is a leading provider of business <strong>and</strong> financial information <strong>and</strong> solutions worldwide. We<br />
specialize in providing online market business information on market research reports, books, magazines,<br />
conference at competitive prices, <strong>and</strong> strive to provide excellent <strong>and</strong> innovative service to our customers.<br />
Contact Details:<br />
<strong>Aarkstore</strong> Enterprise<br />
Phone: +91 998 729 5242<br />
Email: enquiry@aarkstore.com<br />
Our Website: http://www.aarkstore.com
Change language